Skip to main content

Table 6 Adverse events reported by children treated with artemether-lumefantrine or artesunate-amodiaquine

From: Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo

Adverse effects

Number of patients

Artemether-lumefantrine

Artesunate-amodiaquine

D1

D2

D3

D7

Total

D1

D2

D3

D7

Total

Number of patients

61

61

61

60

243

60

60

57

56

233

Asthenia

0

2

1

0

3

13

12

7

0

32

Loss of appetite

0

1

0

0

1

6

7

0

0

13

Vomiting

1

2

0

0

3

8

5

1

0

14

Abdominal pain

0

1

1

1

3

3

3

1

0

7

Headache

0

0

0

0

0

1

1

0

0

2

Pruritus

0

0

0

0

0

1

0

0

0

1

Facial oedema

0

1

2

0

3

0

0

0

0

6

Total

1

7

4

1

13

32

28

9

0

75

  1. The numbers of adverse events are reported on each follow-up day until day 7. If the same child reported the same adverse effects on different days, the total number of cumulative adverse events was reported. None of the children complained of nausea, dizziness, diarrhoea, or icterus. D day after inclusion in the study (day 0 is the first day of inclusion)